CEO:New division will focus on "graphite and graphene [as] transformational materials in evolving technologies relevant to the energy/defense/national security and space sectors."

VANCOUVER, BC, Oct. 1, 2026 /PRNewswire/ -- Graphite One Inc. (TSXV: GPH) (OTCQX: GPHOF) ("Graphite One," "G1" or the "Company"), developing a complete domestic U.S. supply chain for advanced graphite materials, announced today the creation of a new division of the Company, which will be the Company's platform for developing next-generation graphite technologies and supply systems for the energy, technology, and national security sectors.

"This new division will focus on expanding the applications for Graphite One's planned domestic graphite supply chain beyond battery and energy storage systems," said Anthony Huston, CEO of Graphite One. "It stems from our recognition that graphite and graphene are transformational materials in evolving technologies relevant to the energy/defense/national security and space sectors."

Marketing Campaign Update

The Company announces today that as part of its ongoing strategy to raise the profile of Graphite One and its Graphite One Project and the planned synthetic graphite active anode material manufacturing facility ("SG AAM Plant") in the United States, the Company has entered into agreements with Global One Media Group ("Global One"), Emerging Growth, LLC, doing business as TDM Financial ("TDM Financial"), and Frontier Media Inc. ("Frontier Media") (collectively, the "Marketing Agencies") to provide marketing services to enhance visibility with institutional and retail investment community, effective immediately.

Under the terms of the Global One agreement, Global One will provide digital marketing media production, branding, social media management, and content creation for a six (6) month period for a total cost of US$45,000.

Under the terms of the TDM Financial agreement, TDM Financial will provide video, video interviews, content creation, and infographics for a seven (7) month period for a total cost of US$35,000.

Under the terms of the Frontier Media Inc. agreement, Frontier Media will provide online marketing services, including but not limited to creation of marketing campaigns, advertisements, and creation of landing pages for ad campaigns for a six (6) month period ("Term") for a total cost of US$250,000 per month. The Company has an option to extend the Term by providing written notice to Frontier Media at least five (5) business days prior to the end of the Term.

Each of the Marketing Agencies has agreed in providing their respective services to comply with all applicable securities laws and the policies of the TSX Venture Exchange ("TSXV") and the OTC Markets. None of the Marketing Agencies have any interest, directly or indirectly, in the Company or its securities, nor any right or intent to acquire such an interest. Each of the Marketing Agencies may provide additional services to the Company in the future.

There are no performance factors impacting compensation in the agreements and the Marketing Agencies will not receive common shares or options of the Company as compensation. Each of the Marketing Agencies is arm's length to the Company and none of the Marketing Agencies currently own, directly or indirectly, any common shares of the Company, nor do any of them have any right or intent to acquire such an interest.

These agreements remain subject to TSXV approval and this disclosure is made in accordance with the requirements of TSXV Policy 3.4 – Investor Relations, Promotional and Market-Making Activities.

Graphite One's U.S. Supply Chain Strategy

With the United States currently 100% import-dependent for natural graphite, Graphite One is developing a fully integrated U.S.-based supply chain anchored by the Graphite Creek deposit – recognized by the U.S. Geological Survey as the largest graphite deposit in the U.S. and among the largest globally. The Company's current strategy includes:

- Mining at Graphite Creek (Alaska)

- Transporting via the Port of Nome

- Processing into advanced graphite and anode materials in Ohio

- Potential co-located recycling facility to recover graphite and other battery materials, subject to project financing

This integrated approach positions Graphite One to become a cornerstone supplier in a domestic, circular battery materials economy in recognition of graphite's indispensable role in rapidly developing technology sectors. The Company's strategy now includes the creation of a new advanced systems division, which will be the platform for developing next-generation graphite technologies and supply systems for the energy, technology, and national security sectors.

About Graphite One Inc.

GRAPHITE ONE INC. continues to develop its Graphite One Project (the "Project"), with the goal of becoming an American producer of high-grade anode materials that is integrated with a domestic graphite resource. The Project is proposed as a vertically integrated enterprise to mine and process natural graphite and to manufacture artificial and natural graphite anode active materials primarily for the lithium-ion electric vehicle battery and energy storage markets.

On Behalf of the Board of Directors

"Anthony Huston" (signed)

For more information on Graphite One Inc., please visit the Company's website, www.GraphiteOneInc.com

On X @GraphiteOne

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

All statements in this release, other than statements of historical facts, are forward-looking statements, including, without limitation, statements regarding the significance of the creation and development of the new advanced systems division and the actual potential of developing next-generation graphite technologies and supply systems for the energy, technology and national security sectors, the successful development of new graphite technologies, and the timing and availability of project funding for the Company's proposed strategy. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "proposes", "expects", "is expected", "scheduled", "estimates", "projects", "plans", "is planning", "intends", "assumes", "believes", "indicates", "to be" or variations of such words and phrases that state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". The Company cautions that there is no assurance that the Company will be successful in creating and developing its new division or developing new graphite technologies. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continuity of mineralization, uncertainties related to the ability to obtain necessary permits, licenses and title and delays due to third party opposition or regulatory processes (including the EIS), changes in government policies regarding mining and natural resource exploration and exploitation, and continued availability of capital and financing, and general economic, market or business conditions. Further, the Company is in an industry where political, economic, regulatory and social conditions may change over time. Changes in government policies, taxation regimes, security conditions or stakeholder expectations, particularly the dynamic nature of U.S.-China trade relations, may affect the Company's ability to meet its stated goals and objectives. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this press release, and the Company undertakes no obligation to update publicly or revise any forward-looking information, except as required by applicable securities laws. For more information on the Company, investors should review the Company's continuous disclosure filings that are available at www.sedarplus.ca.

SOURCE Graphite One Inc.

Share this article

Proceeds from the facility will support the deployment of compute infrastructure dedicated to customer contracts

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- SharonAI Holdings Inc. (NASDAQ: SHAZ) ("Sharon AI" or the "Company"), a leading Australian Neocloud delivering trusted AI infrastructure, today announced it has entered into its inaugural US$356m committed senior secured, GPU-backed SPV debt facility priced at a fixed rate of 9.95%, excluding fees.

The facility will be secured against the GPUs and associated cash flows, with the contract-backed funding structure reflecting the security and delivery discipline underpinning Sharon AI's platform and marks a further step towards the Company's ambition of delivering gigawatt-scale AI compute capacity across Australia, New Zealand and the broader Asia-Pacific.

The facility includes marquee Australian, Asian and global investors including Goldman Sachs and select large private credit funds. This facility is the first in an expected series of GPU financings supporting the scheduled build out of over 68,000 NVIDIA GPUs deployed by mid-2027.

With the closing of this transaction, Sharon AI will have secured over US$2.6bn of institutional debt and equity capital over the past 10 months, extending the Company's capital markets program and underscoring Sharon AI's ability to access diversified sources of capital as it scales its AI infrastructure platform for a growing customer base of hyperscale, AI natives, government, enterprise, and research organizations.

"As demand for sovereign and secure, trusted AI infrastructure continues to outpace available supply globally, and particularly across Australia, New Zealand and the broader Asia-Pacific, access to scalable debt capital is an important enabler of our growth," said James Manning, Co-founder and Chief Executive Officer of Sharon AI.

"This facility demonstrates how we expect to access debt markets to fund our GPU deployments, leveraging our book of quality customer offtake now standing at a TCV of over US$8.8bn. This is designed to enhance return on equity and ultimately drive increased long-term shareholder value. With a strong balance sheet, growing contracted capacity pipeline and a disciplined approach to capital allocation, we believe we are well positioned to continue scaling our AI platform across the Asia-Pacific region."

Jarden Australia acted as sole financial advisor and arranger.

ENDS

About Sharon AI

Sharon AI (NASDAQ: SHAZ) is a leading Australian Neocloud delivering trusted sovereign AI infrastructure. Through its AI Factory platform and world-class ecosystem of technology and co-location partners, Sharon AI expands access to the scalable capabilities organizations need to build, train and run AI, from model training through to inference and agentic AI. Serving customers globally, Sharon AI helps organizations move faster from AI potential to measurable value. For more information, visit www.sharonai.com.

Media

[email protected]

Investors

[email protected]

Disclosure Information

Sharon AI primarily uses its Investor Relations page (https://sharonai.com/investors/) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. The Company also notes that, at times, it discloses material non-public information through other communication mediums including, but not limited to, its X account (sharon__ai) and/or LinkedIn account (sharon-AI), press releases, and regulatory filings with the SEC, or through conference calls, webcasts, and investor days, etc. that the company may hold.

Forward-Looking Statements

This press release may contain, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which are not historical facts, and which are not assurances of future performance. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "strategy," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions or references to future periods. Examples of such forward-looking statements include but are not limited to express or implied statements regarding Sharon AI's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding:

- Service and product offerings;

- The deployment of assets and expansion of network procurement;

- Sharon AI's ability to engage with additional potential customers;

- Expansion of Sharon AI's data center footprint and capacity;

- The strengthening of Sharon AI's partner network;

- Additional or future GPU financings;

- Complete fulfillment of all customer contracts;

- The impact and effect of debt structures designed to enhance return on equity and to drive stockholder value; and

- The Company's position to continue scaling its AI platform across the Asia-Pacific region.

In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements include, among others, all of the risks described in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K filed with the SEC and other reports subsequently filed with the SEC. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the SEC, which are available at www.sec.gov.

The forward-looking statements and other information contained in this press release are made as of the date hereof and Sharon AI does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

SOURCE SharonAI Holdings Inc.

Share this article

Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency

- Supporting pharmaceutical, medical device, wellness, and research organizations in obtaining standardized sleep data

- Expanding the use of SOMNUM scoring technology to provide clinical analysis services tailored to each customer's research objectives

- AI Technologies Supporting Global Clinical Trials in Drug Development

BOSTON, Oct. 1, 2026 /PRNewswire/ -- More pharmaceutical companies and research organizations are turning to HoneyNaps, an AI-based sleep health technology company, for objective analysis and validation of sleep data. Demand spans clinical trials of sleep medications, evaluations of wellness sleep devices and home-care products, and studies involving positive airway pressure (PAP) therapy and cardiovascular disease. In response, HoneyNaps is broadening the scope of its clinical analysis services.

HoneyNaps has completed registration as a clinical research organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). It combines AI-powered sleep analysis technology with experience supporting clinical trials involving more than 10,000 participants and the capabilities to operate multicenter, multidisciplinary studies. Its clinical sleep data analysis services quantify key physiological measures obtained through polysomnography (PSG), including sleep stages, respiratory events, and arousals, and support the analysis of clinical endpoints aligned with each study's objectives.

Although research objectives vary across sectors, pharmaceutical companies, device developers, and research organizations share a need for objective, consistent sleep data. Evaluating treatment response or device performance requires sleep metrics to be analyzed against consistent criteria while minimizing variability between institutions and scorers. The need to establish reliable and reproducible data is driving growing interest in HoneyNaps' sleep analysis technology.

As demand for sleep data analysis and validation grows across sectors, HoneyNaps is extending its business beyond sleep scoring with its SOMNUM platform into clinical analysis services for the pharmaceutical, wellness, and medical device industries. Data quantifying sleep architecture and continuity, respiratory patterns, and oxygen saturation changes may also serve as foundational evidence for future digital biomarker development.

Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, said, "Pharmaceutical companies, device developers, and research organizations pursue different research objectives, but they share a need for objective and consistent sleep data. As more customers across these sectors turn to HoneyNaps to obtain such data, we are expanding both the applications of our existing scoring technology and the business areas that contribute to revenue."

He added, "We will continue to support the generation of clinical evidence through endpoints suited to each study and standardized analysis criteria, while diversifying our revenue base."

For further information, please contact:

HoneyNaps USA, Inc.

Christine Kwon / Managing Director

Email: [email protected]

Address: 14th Floor, One Broadway, Cambridge, MA 02142, USA

Website: www.honeynaps.com

SOURCE HoneyNaps

Share this article

New Senior Commercial Appointments at Neuromod

- Joe Ghiz joins Neuromod as Chief Commercial Officer to lead the company's global commercial strategy as they expand access to groundbreaking tinnitus treatment device, Lenire.

- Joe Ghiz brings significant experience having held senior global roles at Align Technology, the company behind Invisalign, and Johnson & Johnson.

- Shannon Basham joins Neuromod as VP of Channel Development, having most recently serving as Senior Director of Audiology for Sonova Group in the United States of America.

DUBLIN, Oct. 1, 2026 /PRNewswire/ -- Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer (CCO) and Shannon Basham as VP of Channel Development.

Mr. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function, as Neuromod continues to strengthen its position as the category creator in tinnitus care.

Announcing the appointment, Dr. Ross O'Neill, Neuromod CEO commented:

"We are delighted to welcome Joe Ghiz to Neuromod at a pivotal moment where robust clinical evidence, global regulatory approval, and broad commercial adoption has positioned our company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Mr. Ghiz brings experience from Align Technology, where he helped the company create a new category of aligner, which reshaped how orthodontists and dentists practice and built a $10 billion company as a result."

Mr. Ghiz joins Neuromod from Align Technology, the company behind Invisalign.

During his time at Align Technology, Mr. Ghiz played a key role in one of the most significant transformations in modern orthodontics: the development and scaling of the clear aligner category.

As General Manager of Sales and through multiple global commercial leadership positions, he led strategic initiatives that created new avenues for growth, introduced innovative business models, and accelerated market expansion. By working closely with orthodontists and industry partners, he helped drive Invisalign adoption, strengthen practice performance, and advance patient access to more effective and convenient orthodontic care. His contributions supported rapid global growth and reinforced Align Technology's leadership in the digital transformation of orthodontics.

Mr. Ghiz's experience in establishing a new treatment model within dental and orthodontic practices aligns with Neuromod's goal of positioning Lenire as a new standard of care for tinnitus in ENT and audiology practices.

Prior to Align Technology, Joe spent over a decade at Johnson & Johnson Vision Care where he held leadership roles spanning sales, marketing, and business development. He worked extensively with independent optometrists to accelerate practice growth, improve patient outcomes, and increase access to vision care services. In addition, he led initiatives that advanced the ACUVUE® brand's market leadership, helping position J&J Vision Care as an industry leader.

Commenting on his appointment as CCO, Joe Ghiz said:

"I'm excited to join Neuromod at such an important time in the company's growth. Lenire has already transformed the lives of tens of thousands of tinnitus patients and has the potential to revolutionize tinnitus care as a whole. I look forward to working with Neuromod's leadership team to deliver the commercial strategy required to reach more clinicians and give millions of patients access to life-changing care."

In addition to Joe Ghiz appointment as Chief Commercial Officer, Shannon Basham has joined as Neuromod's VP of Channel Development. Shannon has more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America.

As Sonova's Senior Director of Audiology and Education, Shannon was the market-facing head of audiology for Phonak and Unitron wholesale businesses where she led the strategy and vision for the audiology and clinical education departments.

Prior to her role as Senior Director of Audiology and Education, Shannon spent a decade as the Director of Clinical Training for Phonak. In this role, Shannon was responsible for content development, management, implementation and communication of training and education programs supporting all Phonak product lines. Additionally, Shannon collaborated with the marketing, clinical and sales departments on messaging that highlighted the features of product performance, consumer benefits and dispensing benefits, which supported the realisation of corporate sales objectives.

Shannon joined Phonak from Insound Medical. As InSound's Clinical Training Manager, Shannon was responsible for the management of the national training team and educational content. Shannon collaborated with marketing, clinical, and sales leadership to commercialize and scale InSound's Lyric Hearing Aid which supported InSound's acquisition by Sonova.

About Neuromod Devices

Neuromod Devices is a global medical technology company with offices in Ireland and North America. The company specialises in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.

Neuromod has completed extensive clinical trials that confirmed the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire. For more information about Neuromod visit www.neuromod.com.

About Lenire®

Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device. Bimodal neuromodulation stimulates nerves using two paired stimuli to drive significant relief from tinnitus.

Lenire combines audio stimulation with stimulation to the surface of the tongue that is delivered through a proprietary device trademarked as Tonguetip®.

An appropriately qualified healthcare professional, such as an ENT or audiologist, prescribes Lenire following a comprehensive audiological examination. Patients then complete treatment as advised from the comfort of their own home.

Lenire is backed by the largest volume of clinical research for a tinnitus treatment device. This research has been validated in peer-reviewed and published analyses of tinnitus patients treated with Lenire at independent clinics.

Lenire® has CE-mark certification and is the first and only bimodal neuromodulation to be awarded a De Novo Approval Grant from the US FDA.

Lenire is available in the United States of America, Canada, Europe, and Australia. It is also a treatment option through the United States of America Veterans Affairs.

SOURCE Neuromod Devices

Share this article

New family of finance-specialized large language models led five of six audit control comparisons and reached 97.4 F1 across targeted policy-category cases, 8.7 points above the strongest frontier model tested.

SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- AppZen, the leader in autonomous finance operations, today introduced ZenLM Plus, a new family of finance-specialized large language models built for the decisions at the center of finance operations.

Finance transformation is entering a new phase, moving beyond AI that assists finance teams to AI agents that can perform work autonomously. Achieving this shift requires specialized intelligence, trusted data, executable workflows, and enterprise governance operating as one integrated system.

AppZen has been building toward this vision through the evolution of its ZenLM models and the Mastermind Platform. Mastermind provides the harness, orchestration, workflows, and controls needed to apply that intelligence across finance operations. It intelligently routes each finance task to the model or method best suited to perform it, whether that is a specialized AppZen ZenLM Plus model, deterministic logic, or a frontier model. This enables finance teams to automate more work at a lower cost, while preserving the accuracy, governance, auditability, and evidence required for every decision.

"Autonomous finance requires more than a powerful model," said Anant Kale, CEO and co-founder of AppZen. "It requires the complete stack, with finance-specialized models, proprietary data, intelligent workflows, and enterprise governance working together to make decisions and take action with accuracy, transparency, and control. ZenLM Plus now outperforms the frontier models we tested on expense audit tasks while operating at a lower cost. Combined with AppZen's agent-first platform, it delivers on the promise of finance transformation, with our AI Agents safely performing more work, autonomously, at enterprise scale."

Benchmark results, tested against seven frontier models

AppZen compared ZenLM Plus with seven frontier models: Opus 5, Sonnet 5, Gemini 3.1 Pro, Gemini 3.5 Flash, GPT-5.6 Sol, GPT-5.6 Terra, and GPT-5.6 Luna. For each audit control, every system received the same relevant expense data, supporting documents, and customer configuration. AppZen scored each system on two measures: precision, the share of flagged expenses that were true violations, and recall, the share of true violations the system caught. It then combined the two into an F1 score of 0 to 100, where 100 indicates perfect accuracy.

ZenLM Plus led five of the six individual audit-control comparisons. It achieved an F1 of 97.4 across targeted policy-category cases, compared with 88.3 for GPT-5.6 Sol, the strongest frontier result. ZenLM Plus led all four consolidated policy groups, including advantages of 10.8 points in premium travel and upgrades, 4.2 points in electronic devices and gifts, and 2.5 points in policy and documentation exceptions.

Among the individual controls, the largest advantage appeared in non-conforming receipt detection. ZenLM Plus achieved an F1 of 92.4, 7.2 points ahead of Opus 5. This task requires more than recognizing a document. A payment slip may prove a card was charged without qualifying as a merchant receipt, while an emailed order confirmation may be valid even if it does not resemble a traditional receipt.

ZenLM Plus also led in catching duplicates across reports, receipt itemization verification, and merchant category matching. Receipt verification was the one control where a frontier model performed slightly better: ZenLM Plus achieved 93.3 F1, compared with 94.1 for Gemini 3.1 Pro and Sonnet 5.

"With ZenLM Plus, we are building the intelligence layer finance teams actually need," said Kunal Verma, CTO and co-founder of AppZen. "Our models are trained on real financial documents, policy decisions, and audit outcomes, then evaluated task by task before they reach production. That approach delivered stronger results on most controls we tested at a fraction of the modeled inference cost. And when a frontier model is better for a specific task, AppZen can use it. Our goal is the best outcome for the customer."

ZenLM Plus also delivered the lowest modeled inference cost of any system evaluated. Even GPT-5.6 Luna, the least expensive frontier model tested, was approximately twice as costly per 1,000 audited expense lines, while Opus 5 was approximately 50 times as costly. This advantage makes it practical to apply specialized AI across high-volume audit workflows while maintaining strong performance.

Purpose-built for the decisions finance teams manage every day

ZenLM Plus supports a broad range of finance controls used by Travel & Expense (T&E) teams across AppZen Expense Audit. In this evaluation, ZenLM Plus covered:

- Policy and category decisions: Applies customer-defined rules to premium travel and upgrades, electronic devices and gifts, personal expenses, merchant categories, fuel-service restrictions, and missing-receipt affidavits.

- Receipt validity and transaction verification: Determines whether supporting evidence qualifies as a valid merchant receipt and whether the merchant, date, amount, expense type, and currency are consistent with the submitted expense.

- Documentation and itemization requirements: Verifies that hotel and meal receipts contain the required line-item or daily detail, and that expenses are submitted within the organization's configured time limits.

- Cross-report duplicate detection: Searches across the submitting employee's and other employees' reports to identify the same receipt or underlying purchase submitted more than once.

Depending on the control, ZenLM Plus draws on employee-entered fields, receipt extractions, payment type, a company's configured categories and thresholds, merchant information, card data, and related expense reports. Its judgment reflects how each customer defines risk rather than a general assumption of what a reasonable company would do.

Availability

ZenLM Plus is currently available for select customers within AppZen's Expense Audit. It will be generally available in December 2026. For more information, please visit https://www.appzen.com/mastermind-ai-automation-platform.

About AppZen

AppZen is the leader in autonomous finance operations, helping enterprises scale accounts payable, expense auditing, and compliance without adding headcount. Powered by agentic AI, its digital coworkers execute end-to-end finance workflows with built-in governance, full auditability, and enterprise-grade security. Trusted by the Fortune 500, including Amazon, Boeing, Salesforce, Novartis, JPMorgan Chase, VMware, and ServiceNow, the company serves global enterprises across a wide range of industries, including life sciences, manufacturing, financial services, and higher education. With AppZen, CFOs reduce operating costs by up to 50%, achieve automation rates of 80% or more, and realize measurable ROI within weeks. Learn more at www.appzen.com.

Media Contact

Megan Botta

Pitch Public Relations

[email protected]

SOURCE AppZen

Share this article

HOUSTON and DÜSSELDORF, Germany, Oct. 1, 2026 /PRNewswire/ -- Uniper has joined a growing list of aviation fuel buyers that have reserved future production capacity from Syzygy Plasmonics' NovaSAF™ platform, as commercial momentum behind the company's biogas-to-SAF technology continues to build.

The agreement adds to Uniper's low carbon portfolio and brings additional commercial traction to Syzygy's planned NovaSAF™ facilities in Central and South America, as NovaSAF-1 in Uruguay approaches a final investment decision. More importantly, the agreement for Syzygy's dual-certified pathway helps to enhance the European Union's ability to meet mandate targets for both bio and RFNBO SAF.

Trevor Best, CEO Syzygy Plasmonics: "Uniper's decision to reserve NovaSAF™ capacity reflects the commercial traction our platform is attracting at the moment when it is most needed to meet mandate volumes. Agreements like this affirm that the market is moving to meet EU commission targets and companies like Syzygy have the right product, at the right time, with the right volumes."

Benedikt Messner, SVP New Energies, Uniper: "Uniper is committed to building a diversified portfolio of low-carbon energy solutions that support our customers' decarbonization goals. Securing access to Syzygy's innovative technology is another important step in building our position in a market with significant growth potential and complements our recent announcements in advancing our sustainable fuels strategy."

Bringing certainty to a diversified low carbon supply portfolio

For Uniper, the agreement represents a deliberate step in building a low carbon energy portfolio that includes sustainable aviation fuel. As European aviation faces growing demand under ReFuelEU and CORSIA, securing forward supply from biogas-to-SAF pathways positions Uniper to serve customers in an increasingly dynamic market.

NovaSAF™: a scalable biogas-to-SAF platform

NovaSAF™ is Syzygy Plasmonics' commercial project platform, converting biogas to sustainable aviation fuel using the company's proprietary Rigel photocatalytic reactor. Designed for cost competitive production, NovaSAF™ facilities are planned globally. NovaSAF-1 in Uruguay is at final investment decision, a milestone that reflects the strength and readiness of the platform.

About Syzygy Plasmonics

Syzygy Plasmonics is a Houston based technology company developing light driven reactor technology to decarbonize fuel and chemical production. Its proprietary Rigel photocatalytic reactor enables biogas conversion to sustainable aviation fuel at competitive cost and carbon intensity. Learn more at www.plasmonics.tech.

About Uniper

Düsseldorf-based Uniper is a European energy company with global reach. It has about 7,000 employees and plays a key role in ensuring a secure energy supply in Europe, particularly in its core markets of Germany, the United Kingdom, Sweden, and the Netherlands. Uniper's 18.5 gigawatts of power generating capacity make it a mainstay of reliable power production. Uniper is a leading gas trader and one of Northwestern Europe's most important LNG importers, and its broad procurement portfolio enhances supply security. Uniper's investments in renewables, hydrogen, and other low-carbon energy carriers propel the transformation of the energy system.

Uniper provides energy and services to about 1,000 municipalities and industrial companies in its home market, Germany. Uniper is also Germany's largest operator of gas storage facilities and hydropower plants.

This press release may contain forward-looking statements based on current assumptions and forecasts made by Uniper SE management and other information currently available to Uniper. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Uniper SE does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to modify them to conform with future events or developments.

SOURCE Syzygy Plasmonics

Share this article

Dr. Laura Carstensen, Dr. Eric Verdin, Dr. Robert Waldinger, and Dr. Dean Ornish headline Attilio's inaugural Longevity Event, October 29 and 30, the first longevity event to adhere to Conflict-Free Standards(TM).

ST. PETERSBURG, Fla., Oct. 1, 2026 /PRNewswire/ -- Attilio will hold its inaugural event October 29 and 30, 2026, at Stanford University and the Buck Institute for Research on Aging, bringing many of the world's leading longevity scientists together for a conflict-free program built entirely around the science, with no sponsors.

The event is co-chaired by Dr. Laura Carstensen, founding director of the Stanford Center on Longevity, and Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging and designer of the Dr. Verdin Baseline Assessment(TM), Attilio's host institutions.

They are joined by Dr. Robert Waldinger, Professor of Psychiatry at Harvard Medical School and director of the Harvard Study of Adult Development, the longest running scientific study of adult life, and Dr. Dean Ornish, widely known as the father of lifestyle medicine and founder and president of the Preventive Medicine Research Institute and clinical professor of medicine at the University of California, San Francisco.

The two day program is built as a small, immersive gathering rather than a conference, with collaborative dialogue between attendees and the headliners in place of a lecture hall audience.

The full agenda features additional leading scientists and clinicians. Dr. David Rehkopf, current director of the Stanford Center on Longevity, and Dr. Thomas Rando, the center's co-founder and current director of the Broad Stem Cell Research Center at UCLA, join Verdin on the biology of aging. Dr. Nathan Price, Co-Director of the Center for Human Healthspan at the Buck Institute and a systems biology researcher focused on personalized wellness, and Dr. Mike Stone, founder of a precision medicine practice and former Harvard Medical School faculty, will speak on turning biomarker data into daily habits. Michele Miller joins Verdin for a session on the Dr. Verdin Baseline Assessment(TM).

Additional speakers include Dr. Michael Breus, known publicly as The Sleep Doctor, and Dr. Sahil Chopra, Co-Founder and Chief Medical Officer of Empower Sleep, on sleep and longevity, and Manu Sharma, Founder and CEO of Labelbox and Chief Technology Architect at Attilio, on AI in longevity. Ken Stern, founder of the Longevity Project and host of the Century Lives podcast from the Stanford Center on Longevity, will emcee both days.

Attilio Mission: Democratize access to +100Year Quality Lifespan, to care that has, until now, been reserved for the 1%.

"Attilio exists to democratize and demonetize access to care that used to be reserved for a small number of people," said Paul A. Pagnato, CEO & Founder of Attilio. "This event puts the same science in front of everyone in the room, regardless of what they could otherwise afford."

Learn more about Attilio at www.attilio.com.

Attilio is a Human powered AI Life Optimization Platform(TM), technology, and Stewardship built to help people live longer, healthier lives. Every membership operates under the company's Conflict-Free Standards(TM): no commissions, no revenue sharing, no self-dealing. Attilio launched in September 2026 under CEO & Founder Paul A. Pagnato, working with experts from Stanford University, Harvard University, and the Buck Institute for Research on Aging.

Media Contact

Lia Bliss, Chief Marketing Officer, [email protected]https://attilio.com

SOURCE Attilio One

Share this article

Lutris Pharma Announces Positive Updated Phase 2 Data Demonstrating Durable, Mechanism-Directed Benefit of LUT014 Gel for EGFRI-Induced Acneiform Rash at the EADV Congress

LUT014 0.1% Gel Demonstrated Statistically Significant Improvement in Treatment Success Achieved by 71.8% of Patients Compared with 38.5% for Placebo (p=0.003)

LUT014 0.1% Demonstrated Statistically Significant Improvement in Clinician-Assessed Rash Severity

LUT014 0.1% Significantly Reduced Non-Adherence to EGFRI Therapy and Treatment Benefit Remained Durable Through Day 55

TEL AVIV, Israel, Oct. 1, 2026 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving the quality of life and drug adherence for patients treated with anti-cancer therapies by mitigating dermatological toxicities, today announced positive updated results from its Phase 2, randomized, double-blind, placebo-controlled clinical trial of its lead compound, LUT014. LUT014 is a novel topical B-Raf inhibitor designed to reduce or prevent worsening of dermatological toxicities caused by anti-cancer drugs that target the MAPK pathway through paradoxical MAPK reactivation. The results will be presented in an oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Congress, being held September 30 through October 3 in Vienna, Austria.

The updated data show that LUT014 0.1% gel demonstrated statistically significant improvements across key measures of EGFRI-induced acneiform rash. The composite primary endpoint of Treatment Success was achieved in 71.8% of patients receiving LUT014 0.1% gel compared with 38.5% receiving placebo (p=0.003). Within the composite endpoint, evaluating the component of the clinician reported outcome measure CTCAE acneiform rash v5.0, 56.4% of patients receiving LUT014 0.1% achieved at least a one-grade improvement compared with 15.4% receiving placebo (p=0.0002) and, evaluating the component of the patient-reported outcome measure using the 13 skin-specific questions from FACT-EGFRI-18 questionnaire, 53.8% of patients receiving LUT014 0.1% achieved at least a five-grade improvement compared with 28.2% receiving placebo (p=0.021) The effect of LUT014 was durable on Day 55, with the composite primary endpoint of Treatment Success achieved in 69.2% of patients receiving LUT014 0.1% gel compared with 31.8% receiving placebo (p=0.005). Importantly, non-adherence to the EGFRI therapy occurred in only 10.3% of patients receiving LUT014 0.1% compared with 28.2% receiving placebo (p=0.044), supporting continued EGFRI therapy at prescribed dosing. The safety profile of LUT014 remains favorable, as previously presented.

"Acneiform rash related to EGFR inhibitor therapy is associated with significant symptoms and reduced quality of life for patients. This can contribute to dose delays, reductions and discontinuation of anti-cancer treatment," said Anisha Patel, MD, professor of dermatology at The University of Texas MD Anderson Cancer Center. "These results demonstrate that LUT014 may produce meaningful improvements in EGFRI-induced acneiform rash while supporting patients' ability to remain on their prescribed anti-cancer therapy. Particularly encouraging is the durability of the observed benefit beyond the 28-day treatment period and the activity seen even in the presence of baseline antibiotic use. LUT014's mechanism-directed approach is designed to reverse the suppressed MAP kinase signaling that initiates this toxicity rather than block the EGFRI drug binding or only targeting the downstream inflammatory response."

"We are encouraged by the positive results of our Phase 2 clinical trial in EGFRI-induced acneiform rash in terms of efficacy, safety and tolerability of LUT014," stated Professor Antoni Ribas, M.D., Ph.D., Founder and Board Member of Lutris Pharma. "On the strength of these data, Lutris plans to initiate a Phase 2 study of LUT014 0.1% Gel in daraxonrasib-induced acneiform rash in patients with pancreatic ductal adenocarcinoma. Because LUT014 is a mechanistic drug that reverses the suppressed MAPK signaling, it has the potential to treat acneiform rash induced by other MAPK-pathway inhibitors. Lutris is exploring opportunities to study LUT014 with other MAPK-pathway inhibitors through partnerships and independently."

LUT014 completed a Phase 2 double-blind, placebo-controlled, randomized, multisite study to evaluate the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 28 days in colorectal cancer (CRC) patients who developed CTCAE Grade 2 or non-infected Grade 3 EGFRI-induced acneiform lesions after receiving cetuximab or panitumumab (NCT04759664). The trial enrolled 118 adult CRC patients who received LUT014 0.1% gel (n=39), LUT014 0.03% gel (n=40), or placebo gel (n=39), applied once daily for 28 days, followed by a 28-day observation period. The composite primary endpoint, Treatment Success, was assessed at Day 28 and required at least a one-grade improvement in CTCAE v5.0 acneiform rash or at least a five-point improvement in patient symptoms as measured by the first 13 questions of the skin-specific FACT-EGFRI-18 score, together with the absence of Treatment Failure. Treatment Failure included EGFRI dose reduction, delay or discontinuation due to rash; initiation or escalation of antibiotics for rash; or study-drug discontinuation due to worsening rash.

Presentation Details:

- Presentation Title: Acneiform Rash from EGFR Inhibitor Therapy: Durable, Mechanism-Directed Reduction with Topical LUT014 (B-RAF Inhibitor) in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

- Presenting Author: Anisha Patel, MD, Professor, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX

- Abstract ID: AS-1328

- Session Title: Free Communication 6: Pruritus/Adverse Drug Reactions

- Session Date: Friday, October 2, 2026

- Presentation Time: 11:25 – 11:35 am CET

- Session Location: Hall N

The presentation materials will be available on the Lutris website after the presentation.

About MAPK inhibitor-Induced Rash

Inhibitors of the MAP Kinase (MAPK) pathway are a class of drugs used to treat certain cancers. EGFR inhibitors are among the targeted therapies that inhibit MAPK pathway signaling. EGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin and the EGFR signaling pathway is critical in regulating growth, survival, proliferation, and differentiation of cells. B-Raf is a protein that is a key regulator of the MAPK pathway. Oncogenic EGFR constitutively signals through the MAPK pathway, leading to uncontrolled cell proliferation in various human cancers, including colorectal, lung, head and neck, urinary bladder, pancreatic and breast cancers.

EGFR inhibitors can block the EGFR signal responsible for cell growth and are increasingly being used both as primary therapy as well as in patients who have progressed on prior chemotherapy treatments. Although effective as anti-cancer therapy leading to tumor shrinkage, EGFR inhibitors lead to many adverse reactions, with the majority of patients experiencing dermatological side effects typically manifested as a papulopustular skin rash, also known as acneiform lesions, which can impact quality of life and affect adherence to therapy.

About LUT014

LUT014 is a proprietary, first-in-class, novel small molecule, topical B-Raf inhibitor designed to reduce or prevent worsening of dermatological toxicities caused by anti-cancer drugs that target the MAPK pathway through paradoxical MAPK reactivation. LUT014 is formulated as a gel and designed to be applied to the affected areas of the skin. When a MAPK inhibitor that acts upstream of B-Raf is used for cancer treatment (e.g., EGFR inhibitors and RAS inhibitors), the MAPK pathway reduces or stops signaling. This causes cell death in both the cancer cells and normal cells. While the death of cancer cells is the desired effect, the death of non-cancer cells, such as those of the skin, is not desired and leads to side effects such as acneiform rash. In cells where the MAPK is inhibited, when the B-Raf protein is also inhibited, the MAPK signaling becomes reactivated. This phenomenon is recognized as the paradoxical effect of B-Raf Inhibitors. LUT014 gel harnesses this paradoxical effect to rescue the skin cells. Due to its overwhelmingly local penetration, LUT014's activity is restricted to the skin. To date, LUT014 has shown favorable safety and clinical benefit in a completed a Phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions.

About Lutris Pharma

Lutris Pharma is a privately owned clinical-stage biopharmaceutical company with a mission to improve the quality of life and drug adherence for patients who are being treated with certain anti-cancer drugs. Lutris Pharma's key asset is LUT014, a proprietary, first-in-class, small molecule, topical B-Raf inhibitor formulated as a gel and designed to be applied to affected areas of the skin in patients treated with certain MAPK inhibitors, such as EGFR inhibitors or RAS inhibitors, which causes most patients to experience dermatological toxicities.

For more information, please visit www.lutris-pharma.com.

Contacts:

Rx Communications Group

Michael Miller

+1-917-633-6086

[email protected]

SOURCE Lutris Pharma

Share this article

Now tracking 2,100+ facilities across 10 key European markets, LandGate delivers site-level spatial data via GIS, API, MCP Server, or direct data export.

DENVER, Oct. 1, 2026 /PRNewswire/ -- LandGate, the leading provider of data and grid intelligence for energy and digital infrastructure, today announced the expansion of its spatial platform to map European Data Centers. The new dataset delivers site-level spatial visibility, energy performance metrics, and operational tracking across key international markets, complementing LandGate's domestic layer.

Following its acquisition by Wood Mackenzie in June 2026, LandGate continues to rapidly advance its market footprint and core technology, cementing its role as the primary intelligence layer powering site selection and power procurement worldwide.

"As hyperscale deployment accelerates and AI workloads push power density demands to record highs, site selection across Europe is undergoing a structural shift," said Yoann Hispa, CEO of LandGate. "By bringing site-level spatial intelligence across Europe into our platform, we give developers, site selectors, and energy professionals the tools they need to evaluate land, power, connectivity, and permitting together."

LandGate tracks 2,100+ facilities across the top 10 European markets:

- United Kingdom (500+ Facilities): Dominates coverage in the London and Slough hub. Power connection requests currently exceed 70 GW.

- Germany (450+ Facilities): Centered in Frankfurt. Shaped by the EnEfG Act, which requires new builds to reach a PUE of 1.2 or lower starting July 2026 and use 100% renewable electricity by 2027.

- France (250+ Facilities): Centered in Paris and Marseille. Spurred by major commitments, including Brookfield's €20 billion, 1 GW campus in Cambrai.

- Netherlands (~198 Facilities): Anchored in Amsterdam. Managed by national bans on builds over 10 hectares or 70 MW outside designated zones and regional grid caps through 2030.

- Italy (180+ Facilities): Concentrated in Milan, leveraging robust fiber networks and Mediterranean subsea connectivity.

- Spain (130+ Facilities): Focused in Madrid and Aragón, pairing lower land costs with large-scale solar and wind PPA availability.

- Ireland (122+ Facilities): Centered in Dublin, where data centers consumed 21% of national power in 2023. Regulations mandate on-site dispatchable generation or storage and 80% new renewable sourcing.

- Sweden (121+ Facilities): Prime target for AI workloads in Stockholm, Falun, and Luleå, utilizing hydropower reserves and low ambient temperatures.

- Poland (107+ Facilities): Focused in Warsaw, Katowice, and Poznań, supported by Special Economic Zones (SEZs) and corporate PPAs.

- Switzerland (105+ Facilities): Concentrated in Zurich and Geneva, defined by strict municipal space limits and low-noise cooling rules.

LandGate delivers its dataset across flexible enterprise architectures:

- GIS Platform and DASS: Screen sites visually via interactive web maps.

- API and Direct Export: Ingest complete facility attributes, including gross power, white space, rack capacity, status, PUE, operator contact details, and precise coordinates, directly into private models.

- MCP Server URL: Connect LandGate data directly into enterprise AI agents for natural language querying.

Combined with 6,200+ U.S. facilities and 4,000+ international sites across 160+ countries, LandGate provides a unified view of global digital infrastructure supply.

About LandGate

LandGate is the leading provider of data, grid intelligence, and site selection analytics for the energy and data center sectors. Acquired by Wood Mackenzie in June 2026, LandGate operates as an agile platform powering global capital allocation. Visit www.landgate.com to learn more or request a demo.

SOURCE LandGate

Share this article

PARAMUS, N.J., Oct. 1, 2026 /PRNewswire/ -- NS Pharma, Inc. (Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru Nakai), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 31st annual International Congress of the World Muscle Society held in Hiroshima, Japan from September 29 to October 3, 2026.

Brogidirsen is an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP as an investigational therapy for DMD patients with dystrophin gene mutations that are amenable to exon 44 skipping.

"We are excited by the longer-term data demonstrating the potential for brogidirsen to slow disease progression in DMD patients amenable to exon 44 skipping," said NS Pharma President, Yukiteru Sugiyama, Ph.D. "It is important for us to continue investigating these therapeutic innovations in hopes of providing patients with additional treatment options and renewed hope."

The presented data are based on the investigator-initiated clinical trial conducted by NCNP and its extension study conducted by Nippon Shinyaku. These studies evaluated the efficacy and safety of brogidirsen in 6 participants who received weekly IV dosing.

Findings include:

- Maintenance of motor function – Evaluation demonstrated maintenance or improvement of motor function in participants who remained ambulant during the course of the study. Further, upper limb function was maintained in all participants including those who became non-ambulant during the course of the study.

- Acceptable safety profile – After 5 years of receiving brogidirsen, no serious or severe adverse events, or anaphylaxis related to long-term brogidirsen administration, were reported, and there were no discontinuations.

- Comparison to natural history data – In several measures, the observed functional outcomes compared favorably with the natural history of DMD.

These results suggest the potential of brogidirsen to slow DMD disease progression in patients who are amenable to exon 44 skipping. The extension trial is ongoing to investigate the efficacy and safety of long-term administration. Further, a global Phase II study of brogidirsen is being conducted by Nippon Shinyaku and its subsidiary NS Pharma. Learn more at ClinicalTrials.gov.

About Duchenne Muscular Dystrophy (DMD)

Duchenne is a form of muscular dystrophy that occurs primarily in males. It causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of DMD may include delayed ability to sit, stand or walk. There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications. For more information, please visit wespeakduchenne.com.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary and registered trademark of Nippon Shinyaku Co., Ltd. Backed by over one hundred years of development expertise, NS Pharma is dedicated to delivering life-changing care to people living with complex, rare diseases. For more information, please visit nspharma.com.

US Media Contact: [email protected]

SOURCE NS Pharma, Inc.

Share this article